Skip to main content
SpringerLink
Log in

Lower costs with TNFi vs non-TNFi switch for RA

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. This study was funded by AbbVie, Inc.

  2. Truven Health MarketScan Commercial and Medicare Supplemental database

Reference

  • Zhou ZY, et al. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis. Advances in Therapy : 24 Mar 2016. Available from: URL: http://dx.doi.org/10.1007/s12325-016-0318-5

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lower costs with TNFi vs non-TNFi switch for RA. PharmacoEcon Outcomes News 752, 26 (2016). https://doi.org/10.1007/s40274-016-3020-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3020-6

Search

Navigation